SCHEMBL5666368

SCHEMBL5666368

CCOc1ccccc1NC(=O)OCCN1CCN(c2ccccc2C)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
PKM P14618 1/20 0.48
TP53 P04637 1/20 0.48
FAAH O00519 1/20 0.48
DRD2 P14416 1/20 0.48
CNR1 P21554 1/20 0.48
DRD3 P35462 1/20 0.48
ADRA1D P25100 1/20 0.48
ADRA1A P35348 1/20 0.48
ADRA1B P35368 1/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HTR1A P08908 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657076 0.94 ADRA1D (0.53) KMT2AMAPTUSP2LMNAFAAH
SCHEMBL5656677 0.90 ADRA1D (0.60) KMT2AMAPTUSP2LMNAALDH1A1
SCHEMBL5654298 0.90 ADORA2B (0.51) KMT2AMAPTALDH1A1TDP1PKM
SCHEMBL14457596 0.90 HTR1A (0.50) GAATDP1PKMADRA1DADRA1A
SCHEMBL5654282 0.89 KMT2A (0.59) KMT2AMAPTUSP2LMNAALDH1A1
SCHEMBL5657858 0.89 PKM (0.63) KMT2AMAPTLMNAALDH1A1PKM
SCHEMBL14457602 0.87 MEN1 (0.51) KMT2AMAPTALDH1A1PKMADRA1D
SCHEMBL14457589 0.87 HTR7 (0.47) TDP1PKMDRD2ADRA1DADRA1A
SCHEMBL5657841 0.86 HTR1A (0.55) KMT2AMAPTLMNAGAATDP1
SCHEMBL5655954 0.85 GAA (0.52) KMT2AMAPTLMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C KMT2A 2124/4885MAPT 3644/4885USP2 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.